USP9X silencing in CML cells decreases anti-apoptotic protein MCL-1, which increases sensitivity to imatinib and other apoptotic stimuli [37, 38]. This evidence concerns the gene USP9X and chronic myelogenous leukemia, BCR-ABL1 positive.